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Abstract: Background: Treating recurrent gliomas is a big dilemma in the literature and 
no uniform protocol is approved to treat such disappointing problem. Although 
improvement in the RT techniques, new CTX techniques and new techniques including 
targeted therapy and gene therapy; all fail to dramatically improve the outcome and solve 
the problem of significant mass effect when the recurrent tumor is big So resurgery play 
a role in treating such challenging problem. The aim of the study: to assess the goal and 
outcome of surgery in treatment of recurrent malignant glioma. Methods:  We 
retrospectively analyzed the data of 56 patients who were operated upon for recurrent or 
progressed high grade gliomas in the Mansoura neurosurgery department allover 2007 
to 2016. We have excluded patients with recurrent thalamic gliomas and patients with 
Kps score less than 70. Results: 12 patient underwent sterotactic biopsy for their tumor 
and were sent for adjuvant radiotherapy, 29 patients underwent partial tumor resection 
and gross total resection was done in 15 patients. The median time to progression was 5 
months. All patients were sent after surgery for poster radiotherapy and chemotherapy. 
The median overall survival was 4 months. Conclusion: Recurrent high grade glioma is 
one of unsolved problem and optimal management is no longer available. Redo surgery 
is quiet challenging with higher minorities and no add to overall survival. Surgery is 
indicated to relieve significant mass effect. Outcome of surgery is better for those who 
did aggressive surgical resection at initial surgery than those who did only partial 
resection. 
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Introduction 
High grade gliomas are the most common 
primary brain tumor and the most challenging 
regarding the treatment opportunities.¹⁻²⁻³ 
Safe gross total resection followed by adjuvant 
treatment including radiotherapy and 
chemotherapy (temozolomide) is the standard 
treatment that could be offered to such dismal 
tumors.4 Despite advancement in the 
treatment modalities; the outcome is 
improved mostly in the functional status but 
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the potential survival has not significantly 
improved and recurrence is mostly inevitable. 
Treating recurrent gliomas is a big dilemma 
and no uniform protocol is approved to treat 
such disappointing problem. Although 
improvement in the radiotherapeutic 
techniques making re-irradiation for recurrent 
gliomas is potentially safe and new 
chemotherapeutic techniques and the 
development of new techniques including 
targeted therapy and gene therapy; all fail to 
dramatically improve the outcome and solve 
the problem of significant mass effect when the 
recurrent tumor is big making redo surgery 
play a role in treating such challenging 
problem. 5⁻6  
Surgery for recurrent high-grade glioma 
should be tailored and individualized based on 
the patient’s age, clinical status, Karnofsky 
Performance Status score. The extent of 
resection and numbers of redo surgeries 
played an important role regarding the quality 
of life and expected survival for recurrent 
grade III or IV gliomas.6 The aim of this 
retrospective study is to assess the goal and 
outcome of surgery in treatment of recurrent 
malignant glioma.  
Patients and methods 
We retrospectively analyzed the data of 56 
patients who were operated up on for 
recurrent or progressed high grade gliomas in 
the neurosurgery department, Mansoura 
University during the period from 2007 to 
2016. Previous treatment for those cases was 
surgery followed by adjuvant treatment in the 
form of radiotherapy with or without 
chemotherapy. We have excluded patients 
with recurrent thalamic gliomas and patients 
with Karnofsky Performance Status score less 
than 70. 
Results 
Patient characteristics are shown in Table 
1. Median age was 47.79 years. Thirty-three 
patients were male, and 23 were female. 
Histology was WHO Grade 4 in 44 patients 
and Grade 3 in 12 patients. At last follow-up, 
32 of 56 patients had died. Median follow-up 
from the date of reoperation was 7 months 
(range, 0–94 months) for all patients and 11 
months (range, 0–94 months) for surviving 
patients.  
Predictors of survival 
We chose certain factors to predict the 
survival of our patient from diagnosis and 
from reoperation to be included in this study, 
and these factors are; age, size of 2ry tumor, 
interval between operation, pathology of 2ry 
tumor and treatment offered after reoperation. 
As regard age of patients, median survival 
rate from diagnosis for patients less than 50 
years was 11.00 and 9.00 for patients more 
than 50 years( p value 0.034) figure 1-A; 
median survival rate from reoperation  for 
patients less than 50 years was 5.00 and 4.00 
for patients more than 50 years( p value 0.060) 
figure 1-B 
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TABLE 1 
Patient characteristics 
AGE Mean ± SD 47.79 9.81
Size of 1ry_tumor (CM) Median  Min – Max 5.00 3-7
Time to recurrence (m) Median  Min – Max 5.00 2-15
Size of recurrence (CM) Median  Min – Max 4.00 2.5-7
Survival time (m) Median Min – Max 5.00 1-13
Sex  Male  33 58.9% 
Female 23 41.1%
Tumor location  
RT frontal 8 14.3%
RT T/P 4 7.1%
LF F/T/P 3 5.4%
LF F/T 5 8.9%
LF TEMPORAL 4 7.1%
RT TEMPORAL 4 7.1%
RT P/O 2 3.6%
LF F/P 2 3.6%
RT F/T/P 5 8.9%
CORPUS CALLOSUM 9 16.1%
LF P/O 2 3.6%
LF P 3 5.4%
LF T/P 2 3.6%
LF F 1 1.8%
RT F/P 1 1.8%
RT P 1 1.8%
Pathology of 1ry tumor GBM 39 69.6%%G3 8 14.3%
Primary TTT 
GTR RT 19 33.9%
PTR RT CH 7 12.5%
GTR RT CH 10 17.9%
PTR RT 9 16.1%
STB RT CH 3 5.4%
STB RT 8 14.3%
Pathology of 2dry T GBM 44 78.6%G3 12 21.4%
Surgery complication 
NO 22 39.3%
Lt hemiparesis 7 12.5%
Coma 6 10.7%
Aphasia 2 3.6%
Rt hemiparesis 9 16.1%
Seizures 9 16.1%
CSF leakage 1 1.8%
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Figure 1-A - median survival rate from diagnosis 
according patients age 
 
 
Figure 1-B - median survival rate from reoperation 
according patients age 
 
Survival from diagnosis and from 
reoperation acording to size of 2ry tumor is 
shown in figure 2-A,B. Median survival rate 
from diagnosis  for 2ry tumor less than 5cm in 
size was 11.00 and for more than 5 cm was 7.00 
with p value 0.004,while it was from 
reoperation for tumor less than 5cm 5.00 and 
3.00 for larger tumor size with p value < 0.001. 
 
Figure 2-A - Survival from diagnosis according to 
size of 2ry tumor 
 
 
Figure 2-B - Survival from reoperation according to 
size of 2ry tumor 
 
On the other hand, if we are looking for 
Survival from diagnosis and from reoperation 
according to interval between operation as 
shown in figure 3-A, B.  
We found that the median survival rate 
from diagnosis for patients whom underwent 
another surgery for the tumors in less than 6 
months from the primary surgery was 8.00 and 
its increase to 18.00 for patients did 2nd 
surgery in period more than 6 months from 
first tumor attacking with p value 0.001. 
While median survival rate from 
reoperation for patients whom underwent 
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another surgery for the tumors in less than 6 
months from the primary surgery was 4.00 and 
its increase to 7.00 for patients did 2nd surgery 
in period more than 6 months from first tumor 
attacking with p value < 0.001. 
 
 
Figure 3-A - Survival from diagnosis according to 
interval between operation 
 
 
Figure 3-B - Survival from reoperation according to 
interval between operation 
 
According to pathology of 2ry tumor, 
Survival from diagnosis and from reoperation 
shown figure 4-A, B. 
We found that the median survival rate 
from diagnosis for patients whom 2ry tumor 
pathology was GBM was 9.00 and its 15.00 for 
patients whom 2ry tumor pathology was grade 
3 with p value 0.003.While median survival 
rate from reoperation for patients whom 2ry 
tumor pathology was GBM was 4.00 and its 
7.00 for patients whom 2ry tumor pathology 
was grade 3 with p value 0.011. 
 
 
Figure 4-A - Survival from diagnosis according to 
pathology of 2ry tumor 
 
 
Figure 4-B - Survival from reoperation according to 
pathology of 2ry tumor 
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Finally, According to treatment offered after reoperation, Survival from diagnosis (Table 2, 
figure 5-A) and from reoperation (Table 3, figure 5-B). 
 
TABLE 2 
Survival from diagnosis according to treatment offered after reoperation 
TTT_offered Total N N of Events Censored Median 
survival time 
P 
N Percent 
GTR_RT_CHT 6 6 0 0.0% 12.000 ˂0.001 
PTR 2 2 0 0.0% 6.000 
GTR_CHT 15 15 0 0.0% 18.000 
PTR_RT 1 1 0 0.0% 11.000 
PTR_CHT 18 18 0 0.0% 9.000 
PTR_RT_CHT 8 8 0 0.0% 9.000 
PTR_DC 6 6 0 0.0% 4.000 
Overall 56 56 0 0.0% 9.000 
 
 
Figure 5-A - Survival from diagnosis according to treatment offered after reoperation 
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TABLE 3 
Survival from reoperation according to treatment offered after reoperation 
TTT_offered Total N N of Events Censored Median 
survival time 
P 
N Percent 
GTR_RT_CHT 6 6 0 0.0% 7.000 ˂0.001 
PTR 2 2 0 0.0% 1.000 
GTR_CHT 15 15 0 0.0% 8.000 
PTR_RT 1 1 0 0.0% 6.000 
PTR_CHT 18 18 0 0.0% 4.000 
PTR_RT_CHT 8 8 0 0.0% 3.000 
PTR_DC 6 6 0 0.0% 1.000 
Overall 56 56 0 0.0% 5.000 
 
 
Figure 5-B - Survival from reoperation according to treatment offered after reoperation 
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In our current study we have different patient complications varied from hemiparesis, coma, 
CSF leakage, and aphasia (Table 4) 
TABLE 4 
Patient complications 
 Sex 
Male Female  
Surgery 
complication 
NO Count 14 8 
 
 
% 
63.6% 36.4% 
Lt hemiparesis Count 6 1 
 
 
% 
85.7% 14.3% 
Coma Count 4 2 
 
 
% 66.7% 33.3% 
Aphasia  Count 1 1 
 
 
% 
50.0% 50.0% 
Rt hemiparesis Count 5 4 
 
 
% 55.6% 44.4% 
Seizures  Count 3 6 
 
 
% 
33.3% 66.7% 
CSF leakage Count 0 1 
 
 
% 0.0% 100.0% 
 
Treating recurrent high-grade gliomas is a 
big dilemma and debate still exist in the 
literature about the value of redo surgery in 
improving the overall prognosis of such 
dismal tumors. Patient age and Karnofsky 
Performance Status (KPS) are very important 
detectors for the quality and duration of 
survival after reoperation. Patients with   
recurrent high-grade glioma with KPS more 
than 70 have better outcome than those less 
than 70. Age and preoperative KPS score had a 
significant effect on duration of high-quality 
survival after 
reoperation.8⁻¹²⁻¹³⁻¹4⁻¹5⁻¹6⁻¹7⁻¹9⁻²º⁻²¹  
Some studies compared the quality of 
survival and duration of survival for patients 
with recurrent high-grade gliomas who 
offered re-operation to those who not 
operated up on. One study found a 9-month 
survival (operated group) compared with 5.75 
months (Non-operated group). 9⁻²²⁻²5⁻²6⁻²7 
Many published data showed 5-50% 
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improvement in KPS after re-operation for 
recurrent high-grade gliomas.     
Improvement in the adjuvant treatment 
protocols with the use of conformal 
fractionated radiotherapy with the use of 
temozolomide chemotherapy helped to 
improve the clinical outcome and overall 
survival for high-grade glioma.  Despite such 
improvement; the chance of tumor 
progression or recurrence still exist and still 
there is a big debate if adjuvant treatment 
alone is enough for recurrence or there is a role 
for re-operation.4 In a one retrospective study 
done by on 65 patients who underwent re-
operation for progressing high grade gliomas. 
Median time to second surgery was 7.1 
months. The indications to reoperation were 
increase in the tumor size on magnetic 
resonance imaging, new neurological deficit, 
manifestation of increased intracranial 
pressure and epilepsy. The authors found 
better overall survival for those who did re-
operation the those who did not.9  Many other 
reports addressed such controversial problem 
and they found that outcome of re-operation 
for recurring high-grade gliomas is 
multifactorial and more favorable outcome 
was found for those patients with age 50 years 
or less, time interval more than 9 months 
between operations, achieving gross total 
resection (GTR), and KPS scores 70 at 
reoperation.9⁻²²⁻²5  
Some studies addressed the role of either 
radiotherapy plus temozolimide or 
temozolimide alone for treating progressing 
high-grade gliomas and despite initial good 
results; the found less capabilities of achieving 
good tumor control and overall survival 
compared to re-operation with adjuvant 
treatment. However; there was no difference in 
outcome of the patient functional status.¹¹       
Improvement in neurosurgical techniques, 
neuro-anesthesia, and post-operative ICU care 
minimized procedure related morbidities and 
mortalities. However, proper patient selection 
is very important to choose the case who might 
get benefit from re-operation. Beside the 
patient age, KPS, the time to recurrence; other 
factors may play an important role be 
considering the outcome. 
5⁻7⁻8⁻¹º⁻¹²⁻¹³⁻¹5⁻¹8⁻²¹⁻²³⁻²8 
The tumor size and the degree of central 
necrosis play an important role regarding the 
outcome and it was found in some studies that 
the prognosis was favorable with patients 
having tumor necrosis rather than tumor 
recurrence. Smaller tumor volume had a more 
favorable outcome compared with bigger 
tumor volume at time of re-operation. The 
extent of tumor removal is another prognostic 
indicator for the outcome which is also 
dependent on the tumor size and location with 
more favorable outcome occur with achieving 
adequate gross total resection at both the time 
of primary and re-operations. It was found the 
re-operation for recurrent tumor after initial 
gross total resection has a better outcome than 
after partial resection or just biopsy.²4 Gross 
total resection (GTR) is recognized by many 
studies as an independent predictor of 
improved survival in patients with recurrent 
high-grade glioma. It was found that the 
residual tumor volume has its impact on 
outcome of temozolomide chemotherapy after 
re-operation.² One study on recurrent high-
grade gliomas reported a median survival of 
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11months after GTR compared to 5 months 
after only partial resection disregarding 
patient age and performance status.²³ In 
another study; authors analyzed a series of 107 
patients with re-operation for recurring high-
grade glioma. They addressed the value of the 
extent of tumor resection at the initial and 
subsequent surgery. The found the best 
survival outcome with subtotal resection at the 
initial surgery and GTR at re-operation with 
median overall survival of 16.7-month and the 
worst outcome with partial resection at both 
surgery with 7.4 median overall survival.5                         
Patients age play an important role in 
overall prognosis for recurrent high-grade 
gliomas and the younger the age the better the 
prognosis. Although some centers did not 
offer surgery for elderly with recurrent high-
grade gliomas; some studies concluded that 
surgery should be considered for all patients 
with favorable KPS disregarding the age of the 
patient.²9                        
The goal of surgery for recurrent high-
grade gliomas is to do safe adequate resection 
with limited morbidities. The potential 
morbidities for re-operation was studied in 
many case series. Some studies showed no 
difference in the incidence of morbidities 
while others showed higher chance of surgery 
related morbidities.  In one study; 18% patients 
had neurological deterioration for surgery of 
recurrent cases compared to 8% neurological 
deterioration after the initial surgery. 7                                          
Conclusion: Although advancement in 
neurosurgical techniques; recurrent high 
grade glioma is one of unsolved problem for 
neurosurgical practice and optimal 
management is no longer available. Redo 
surgery is quiet challenging with higher 
minorities and no add to overall survival. 
Surgery is indicated to relieve significant mass 
effect. Outcome of surgery is better for those 
who did aggressive surgical resection at initial 
surgery than those who did only partial 
resection. But if resurgery is indicated due to 
mass effect of the tumor may help to improve 
survival and should be considered in patients 
with a favorable KPS score at time resugery. 
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